TriSalus Life Sciences Management
Management criteria checks 1/4
TriSalus Life Sciences' CEO is Mary Szela, appointed in Jan 2018, has a tenure of 6.83 years. total yearly compensation is $2.69M, comprised of 19.2% salary and 80.8% bonuses, including company stock and options. directly owns 0.86% of the company’s shares, worth $1.17M. The average tenure of the management team and the board of directors is 2.8 years and 2.9 years respectively.
Key information
Mary Szela
Chief executive officer
US$2.7m
Total compensation
| CEO salary percentage | 19.2% |
| CEO tenure | 6.8yrs |
| CEO ownership | 0.9% |
| Management average tenure | 2.8yrs |
| Board average tenure | 2.9yrs |
Recent management updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$58m |
| Jun 30 2024 | n/a | n/a | -US$57m |
| Mar 31 2024 | n/a | n/a | -US$68m |
| Dec 31 2023 | US$3m | US$518k | -US$63m |
| Sep 30 2023 | n/a | n/a | -US$53m |
| Jun 30 2023 | n/a | n/a | -US$59m |
| Mar 31 2023 | n/a | n/a | -US$51m |
| Dec 31 2022 | US$861k | US$464k | -US$50m |
Compensation vs Market: Mary's total compensation ($USD2.69M) is above average for companies of similar size in the US market ($USD652.28K).
Compensation vs Earnings: Mary's compensation has increased whilst the company is unprofitable.
CEO
Mary Szela (61 yo)
6.8yrs
Tenure
US$2,692,830
Compensation
Ms. Mary T. Szela, M.B.A. B.S.N. is Director of LARONDE, Inc. from February 2024. Ms. Szela served as an Independent Director at Prometheus Biosciences, Inc. since February 17, 2021 until June 16, 2023. Ms...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 6.8yrs | US$2.69m | 0.86% $ 1.2m | |
| CFO & Director | 2.8yrs | US$1.39m | 1.72% $ 2.3m | |
| Vice President of Operations | no data | no data | no data | |
| Chief Scientific & Manufacturing Officer | no data | no data | 0.22% $ 300.4k | |
| Senior VP of Investor Relations & Treasurer | 1.3yrs | no data | no data | |
| Senior Vice President of Corporate Development & Strategy | no data | no data | 0.033% $ 44.4k | |
| Chief Regulatory Officer | 3.7yrs | US$652.03k | 0.046% $ 61.6k | |
| President of Commercial Operations | 1.2yrs | no data | no data |
2.8yrs
Average Tenure
62yo
Average Age
Experienced Management: TLSI's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 6.8yrs | US$2.69m | 0.86% $ 1.2m | |
| CFO & Director | 3.1yrs | US$1.39m | 1.72% $ 2.3m | |
| Independent Director | 1.3yrs | US$263.70k | 1.69% $ 2.3m | |
| Independent Chairman | 8yrs | US$323.28k | 4.11% $ 5.6m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Chief Medical Officer & Chairman of Scientific Advisory Board | 6.8yrs | US$1.61m | 0.058% $ 78.8k | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
2.9yrs
Average Tenure
64yo
Average Age
Experienced Board: TLSI's board of directors are not considered experienced ( 2.9 years average tenure), which suggests a new board.